ALXO (ALX Oncology) Net Assets per Single Share

Official company branding of ALX Oncology (ALXO)

ALX Oncology Holdings (ALXO) is investing in the expansion of its efvorpacept pipeline to capture the oncology market. This GURU.Markets chart of the stock's book value reflects net asset dynamics, where the current value is 0.99. The company develops proteins to unmask tumors, enhancing therapy, and is implementing software automation for the digital processing of clinical test data.

ALXO ALX Oncology Net Asset Value per Share (07/04/2022 - 10/31/2026)

ALXO (alxoncology.com): analytical breakdowns and indicator data

- share price and expert price forecast:
Stock Quotes ALX Oncology Holdings|ALXO - Broker Consensus Forecast
- business market valuation indicators:
Market Value ALX Oncology Holdings|ALXO - Total Enterprise Value
- shareholders' equity book value data:
Net Assets per Single Share ALX Oncology|ALXO - Total Stockholders' Equity|Market Value to Book Value Ratio alxoncology.com|ALXO - Total Business Assets
- debt and liquidity details:
Total Debt to Capital ALX Oncology Holdings|ALXO - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity ALX Oncology|ALXO - Company Cumulative Debt|Debt to Book Capitalization Ratio ALX Oncology Holdings|ALXO - Company Long-Term Debt|Company Short-Term Debt ALX Oncology|Quick Ratio alxoncology.com
- earnings and multiples data:
ALXO - Annual Net Income
Basic company analysis:ALXO - ALX Oncology Holdings
Manufactured products of ALX Oncology

ALX Oncology Holdings (ALXO) is developing innovative CD47 immunotherapy, creating the safe drug evorpacept to combat tumors. By analyzing the book value per common share trend, an investor can see the net asset value minus all liabilities, which allows for an assessment of the business's real intrinsic value stripped of market noise. The steady growth of this metric confirms the capitalization of intellectual property and the company's fundamental stability.

Competitor analysis for ALX Oncology Holdings

IBRX: Accounting Value per Share|IMCR (Immunocore Corp) - Equity per Share|Janux Therapeutics (JANX) - Net Assets per Single Share|Net Asset Value per Share arcusbio.com (RCUS)|Net Assets per Single Share Zymeworks|Net Asset Value per Share Tango Therapeutics Inc TNGX|Net Assets per Single Share Iovance (IOVA)|Immatics Biotechnologies - Equity per Share|Book Value per Share XNCR (Xencor, Inc.)|CMPX - Accounting Value per Share|REPL - Net Assets per Single Share|Net Asset Value per Share Lyell|Innate Pharma, S.A. (IPHA) - Net Assets per Single Share|PYXS (Pyxis Oncology) - Net Assets per Single Share|Net Assets per Single Share Compugen Ltd|Net Asset Value per Share iobiotech.com IOBT|Book Value per Share STRO|MiNK Therapeutics Inc. (INKT) - Book Value of One Share|Werewolf Therapeutics, Inc. - Accounting Value per Share|Immix Biopharma Inc. (IMMX) - Net Asset Value per Share|CUE: Accounting Value per Share|Accounting Value of a Share PDSB (PDS Biotechnology)|SONN: Book Value per Share|MAIA - Net Assets per Share|Net Assets per Single Share Liminatus Pharma Corp|Accounting Value per Share Lava Tx (LVTX)|Net Assets per Single Share NextCure, Inc. (NXTC)|Accounting Value per Share leaptx.com LPTX|Intensity Therapeutics, Inc. - Accounting Value per Share|Book Value per Share Sensei Biotherapeutics Inc SNSE|TOVX - Net Assets per Single Share|GRTS (Gritstone bio, Inc.) - Equity per Share|Kineta, Inc. (KA) - Net Assets per Single Share|Net Asset Value per Share neximmune.com (NEXI)|Accounting Value per Share TSBX|VCNX - Book Value of One Share|Accounting Value per Share HARP (Harpoon Tx)